MID1IP1 Antibody, HRP conjugated

Key Features

• Target Protein: MID1IP1 (Q9NPA3 in humans), a 183-amino acid protein with roles in regulating lipogenesis and stabilizing microtubules .

• Conjugation: Horseradish peroxidase (HRP) is covalently linked to the antibody, enabling enzymatic detection via chromogenic substrates (e.g., TMB, DAB) .

• Host Species: Typically rabbit-derived polyclonal or monoclonal antibodies .

• Reactivity: Primarily human, with cross-reactivity to mouse and rat in some formulations .

Applications

Role in Cancer Metastasis

MID1IP1 promotes hepatocellular carcinoma (HCC) progression by:

• Upregulating FRA1: Enhances transcriptional activity of matrix metalloproteinase-9 (MMP9), facilitating extracellular matrix degradation and metastasis .

• Stabilizing c-Myc: Colocalizes with c-Myc via ribosomal proteins L5/L11 and CNOT2, driving oncogenic signaling .

• Inhibiting Apoptosis: Depletion of MID1IP1 increases sub-G1 cell populations and TUNEL-positive cells in HCC models .

Mechanistic Insights

Western Blot Validation

• Target Band: ~23 kDa (observed) vs. ~20 kDa (calculated) .

• Controls:

  • Positive: HEK293T lysates overexpressing MYC-tagged MID1IP1 .

  • Negative: Mock-transfected cells .

• Sensitivity: Detects 1 µg/ml in WB .

ELISA Performance

• Sensitivity: 1:8,000 dilution in ELISA (A83636) .

• Specificity: Cross-reacts with synthetic peptide C-HTVLSKLTRK .

Therapeutic and Diagnostic Implications

• Targeting MID1IP1: Inhibition reduces c-Myc stability and synergizes with CNOT2 depletion to enhance apoptosis in HCC .

• Biomarker Potential: Elevated MID1IP1 correlates with aggressive HCC phenotypes and poor prognosis .